Preexisting tumor-resident T cells with cytotoxic potential associate with response to neoadjuvant anti-PD-1 in head and neck cancer

Keyphrases

• Tumor 100%
• Head-and-neck Cancer 100%
• Cytotoxic Activity 100%
• Neoadjuvant 100%
• Anti-PD-1 100%
• Resident T Cells 100%
• Tumor Microenvironment 60%
• Pathological Response 40%
• CD8+ T Cells 40%
• Programmed Death-ligand 1 (PD-L1) 40%
• Head-and-neck Squamous Cell Carcinoma (HNSCC) 40%
• Tumor-infiltrating Lymphocytes 40%
• PD-1 Blockade 40%
• CD8+ Tumor-infiltrating Lymphocytes 40%
• Antitumor T Cells 20%
• Two-dose 20%
• CD103 20%
• Tumor-specific 20%
• Phase II Trial 20%
• Tumor Biopsy 20%
• Pre-surgical 20%
• Definitive Therapy 20%
• Response Mechanism 20%
• Non-responders 20%
• Tumor Antigen 20%
• Single-cell Analysis 20%
• Viable Tumor 20%
• Locally Advanced 20%
• Tissue-resident Memory 20%
• Post-neoadjuvant 20%
• Pembrolizumab 20%
• Anti-programmed Cell Death Protein 1 20%
• Anti-PD-1 Immunotherapy 20%
• Pathological Tumor Response 20%
• Postneoadjuvant Therapy 20%
• Clonal Replacement 20%

Medicine and Dentistry

• Neoplasm 100%
• T Cell 100%
• Head and Neck Cancer 100%
• Tumor Infiltrating Lymphocyte 100%
• Tumor Microenvironment 75%
• CD8 Antigen 50%
• Cytotoxic T-Cell 50%
• Head and Neck Squamous Cell Carcinoma 50%
• Tumor Biopsy 25%
• Immunotherapy 25%
• Tumor 25%
• Recurrent Disease 25%
• Specific Tumor 25%
• Neoadjuvant Therapy 25%
• Programmed Death 1 Receptor 25%
• Tumor Antigen 25%
• Pembrolizumab 25%

Immunology and Microbiology

• T Cell 100%
• Neck 100%
• Tumor-Infiltrating Lymphocytes 100%
• CD8 50%
• Cytotoxic T-Cell 50%
• Squamous Cell 50%
• Immunotherapy 25%
• Tumor Antigen 25%
• Dynamics 25%
• Single Cell Analysis 25%
• Programmed Death 1 Receptor 25%
• Pembrolizumab 25%
• Pretreatment 25%